Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) Save

Date Added
March 10th, 2020
PRO Number
Pro00095068
Researcher
Patrick O'neil

List of Studies


Profiles_link
Keywords
Drug Studies, Obesity, Weight Control
Summary

Tirzepatide is an investigational medication that has been studied for the treatment of diabetes when administered once a week by self-injection. In these trials people who received the medication also lost some weight. This study is being done to see how safe tirzepatide is and how well it will work to help people who are obese or overweight to lose weight, when it is used along with a reduced-calorie diet and increased physical activity.

Participants will be randomly assigned to one of three doses of tirzepatide or to a placebo (inactive look-alike drug). They will be followed for either 72 or 176 weeks depending on the results of an initial test of blood sugar control.

Institution
MUSC
Recruitment Contact
Mary Harley
843-792-5428
harleyma@musc.edu

Change_preferences

-- OR --

Create_login